C5 inhibitor avacincaptad pegol treatment for geographic atrophy: A comprehensive review.
Immunotherapy
; : 1-12, 2024 Jul 29.
Article
in En
| MEDLINE
| ID: mdl-39073397
ABSTRACT
Geographic atrophy (GA) remains a leading cause of central vision loss with no known cure. Until recently, there were no approved treatments for GA, often resulting in poor quality of life for affected patients. GA is characterized by atrophic lesions on the retina that may eventually threaten the fovea. Emerging treatments have demonstrated the ability to reduce the rate of lesion growth, potentially preserving visual function. Avacincaptad pegol (ACP; Astellas Pharma Inc), a complement component 5 inhibitor, is an FDA-approved treatment for GA that has been evaluated in numerous clinical trials. Here we review the current clinical trial landscape of ACP, including critical post hoc analyses that suggest ACP may reduce the risk of severe loss among patients with GA.
Geographic atrophy (GA) is an advanced form of eye disease age-related macular degeneration. In people with GA, light-sensitive cells at the back of the eye (the retina) start to die, forming lesions. GA lesions usually get bigger over time and can lead to blindness. New medicines are being studied that work by slowing the growth of GA lesions. Avacincaptad pegol (ACP) is one medicine that acts on the immune system and is designed to block the C5 protein, helping stop the immune system from attacking cells in the retina. Based on clinical studies, ACP was shown to slow the growth of GA over time and has been approved by the FDA. This review article summarizes research on ACP.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Immunotherapy
Journal subject:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Year:
2024
Document type:
Article
Affiliation country:
Estados Unidos